NVTA.Q Stock Overview A medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Invitae Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Invitae Historical stock prices Current Share Price US$0.0004 52 Week High US$1.25 52 Week Low US$0.000001 Beta 2.8 1 Month Change -42.86% 3 Month Change -76.47% 1 Year Change -99.97% 3 Year Change -100.00% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates
Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients Jul 22 First Amended Disclosure Statement Approved for Invitae Corporation Jun 15
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million. Apr 26
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance Apr 11
Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification Mar 12
Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023 Mar 06 See more updates
Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients Jul 22 First Amended Disclosure Statement Approved for Invitae Corporation Jun 15
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million. Apr 26
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance Apr 11
Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification Mar 12
Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023 Mar 06 Motion for Asset Sale Filed by Invitae Corporation Feb 15
Invitae Corporation Filed for Bankruptcy Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index The New York Stock Exchange to Commence Delisting Proceedings against Invitae Feb 07
Invitae Corporation May File for Bankruptcy Feb 06
New minor risk - Market cap size Feb 06
Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely Dec 20
Invitae Corporation Announces Board Changes Dec 12
Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023 Nov 18
Price target decreased by 11% to US$1.31 Nov 18
Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer Nov 17
Consensus EPS estimates fall by 119% Nov 15
New major risk - Financial position Nov 13
Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023 Nov 10
Price target increased by 30% to US$1.92 Nov 10
Third quarter 2023 earnings: EPS misses analyst expectations Nov 10
Invitae Corporation to Report Q3, 2023 Results on Nov 08, 2023 Nov 02
Invitae Corporation Announces Findings from the Study to Date on Uncertain Results from Hereditary Disease Genetic Testing Oct 26
Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023 Oct 20
Price target decreased by 14% to US$1.58 Oct 18
Invitae Announces Results of Its Collaborative Study on Universal Hereditary Cancer Genetic Testing in All Patients with Breast Cancer in A Rural Population in the Annals of Surgical Oncology Oct 13
Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023 Sep 28
Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard Sep 24
Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard Sep 23
New major risk - Financial position Sep 19 Invitae Corporation Announces Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer
Price target decreased by 13% to US$1.70 Aug 17
Consensus EPS estimates fall by 34% Aug 15
Invitae Corporation Provides Revenue Guidance for the Year 2023 Aug 11
Invitae Corporation Provides Revenue Guidance for the Year 2023 Aug 10
Price target decreased by 8.2% to US$1.87 Aug 09
Second quarter 2023 earnings: EPS misses analyst expectations Aug 09
Invitae: Revenue Troubles Build Aug 09 Invitae Corporation to Report Q2, 2023 Results on Aug 08, 2023 Jul 28
Invitae Is Treading In Competitive Waters Jul 16 Invitae Corporation Announces Executive Changes
Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares Jun 26
Invitae Corporation Announces Nine Studies to Be Presented At the 2023 American Society of Clinical Oncology Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology May 27
Invitae Announces CFO Changes May 26
President recently sold US$54k worth of stock May 21
Invitae Corporation Announces It Intends to Appeal the Verdict Delivered by A Jury At the United States District Court May 17
Consensus EPS estimates fall by 19% May 16
First quarter 2023 earnings: EPS misses analyst expectations May 10
Price target decreased by 10.0% to US$2.26 Mar 05
Full year 2022 earnings: EPS misses analyst expectations Mar 01
Invitae Corporation to Report Q4, 2022 Results on Feb 28, 2023 Feb 15
Price target decreased by 7.4% to US$2.51 Jan 31
Invitae Corporation Appoints William H. Osborne to its Board of Directors Jan 31
Invitae: What Happened At The JP Morgan Health Conference Jan 19
Invitae guides Q4 revenue above estimates Jan 09
Director recently sold US$115k worth of stock Dec 23
Invitae Likely Hasn't Reached The Bottom Yet Dec 15
Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research Dec 08
Invitae Launches Rare Patient Network for Pediatric Patients with Rare Neurodevelopmental Diseases Dec 02
Consensus forecasts updated Nov 16
Invitae: This Turnaround Could Be Painful Nov 15
Invitae Corporation Reiterates Earnings Guidance for the Year 2022 Nov 10
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 09
Invitae Corporation Reports Asset Impairments for the Third Quarter Ended September 30, 2022 Nov 09
Invitae GAAP EPS of -$1.27 misses by $0.43, revenue of $133.54M beats by $2.16M Nov 08
Invitae Corporation Study Shows Therapy Informed by Genetic Testing Reduces Seizures in Some Patients with Epilepsy Nov 01
Invitae Corporation to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Price target decreased to US$2.71 Oct 19
Invitae Stock: Losses And Debt Suggest Bearish Sentiment Is Deserved Sep 22
Why Invitae Corporation Could Underperform Aug 17
Invitae Corporation Reiterates Revenue Guidance for the Year 2022 Aug 10
Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines Aug 09 Shareholder Returns NVTA.Q US Healthcare US Market 7D 0% 3.5% -0.8% 1Y -100.0% -0.07% 25.2%
See full shareholder returns
Return vs Market: NVTA.Q underperformed the US Market which returned 15.9% over the past year.
Price Volatility Is NVTA.Q's price volatile compared to industry and market? NVTA.Q volatility NVTA.Q Average Weekly Movement 642.7% Healthcare Industry Average Movement 8.0% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.3%
Stable Share Price: NVTA.Q's share price has been volatile over the past 3 months.
Volatility Over Time: NVTA.Q's weekly volatility has increased from 571% to 643% over the past year.
About the Company Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners.
Show more Invitae Corporation Fundamentals Summary How do Invitae's earnings and revenue compare to its market cap? NVTA.Q fundamental statistics Market cap US$114.60k Earnings (TTM ) -US$1.44b Revenue (TTM ) US$481.58m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NVTA.Q income statement (TTM ) Revenue US$481.58m Cost of Revenue US$350.95m Gross Profit US$130.64m Other Expenses US$1.57b Earnings -US$1.44b
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -5.03 Gross Margin 27.13% Net Profit Margin -299.14% Debt/Equity Ratio -124.7%
How did NVTA.Q perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/08/05 17:20 End of Day Share Price 2024/08/02 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Invitae Corporation is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raymond Myers Benchmark Company Steven Wardell Chardan Capital Markets, LLC Daniel Leonard Credit Suisse
Show 11 more analysts 
